3 results match your criteria: "Shinshu University School of Internal Medicine[Affiliation]"
Successful Retreatment With ADOC Chemotherapy in Relapsed Thymic Carcinoma: Experiences in Two Cases.
World J Oncol
February 2012
First Department of Internal Medicine, Shinshu University School of Internal Medicine, 3-1-1, Asahi Matsumoto, Japan.
The optimal second-line chemotherapeutic regimen for thymic carcinoma remains uncertain and predictive factors for the response have not been identified. We encountered two cases of relapsed thymic carcinoma with recurrence 1.5 and 8 years after initial response to cisplatin/doxorubicin/vincristine/cyclophosphamide (ADOC) chemotherapy.
View Article and Find Full Text PDFSalvage chemotherapy with amrubicin and platinum for relapsed thymic carcinoma: experience in six cases.
Med Oncol
June 2010
First Department of Internal Medicine, Shinshu University School of Internal Medicine, 3-1-1 Asahi Matsumoto, 390-8621 Matsumoto, Japan.
It has been reported that cisplatin-based chemotherapy shows beneficial effects in certain patients with advanced thymic carcinoma. However, the usefulness of salvage therapy has not been reported. We focused on a new anthracycline agent, amrubicin, combined with platinum compounds as salvage chemotherapy in patients with thymic carcinoma.
View Article and Find Full Text PDFSalvage chemotherapy with carboplatin and paclitaxel for cisplatin-resistant thymic carcinoma--three cases.
Anticancer Res
January 2007
First Department of Internal Medicine, Shinshu University School of Internal Medicine, 3-1-1, Asahi Matsumoto, Japan.
Article Synopsis
- The best chemotherapy treatment for thymic carcinoma is still unclear, and there’s little information about salvage therapy for this cancer.
- In three cases of unresectable, locally advanced thymic carcinoma that didn’t respond to cisplatin, patients were given salvage chemotherapy with carboplatin and paclitaxel.
- Two of the patients had a partial response, while one had a minor response, indicating that thymic carcinoma may be sensitive to these drugs, especially in combination with platinum-based therapies.